Herombopag ( DrugBank: - )


2 diseases
IDDisease name (Link within this page)Number of trials
60Aplastic anemia1
63Idiopathic thrombocytopenic purpura1

60. Aplastic anemia


Clinical trials : 245 Drugs : 318 - (DrugBank : 86) / Drug target genes : 44 - Drug target pathways : 166
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05660785
(ClinicalTrials.gov)
December 1, 202223/11/2022Herombopag Added to Cyclosporine in Non Severe Aplastic AnemiaThe Efficacy and Safety of Herombopag Combined With Cyclosporine for Patients With Non Severe Aplastic AnemiaNon Severe Aplastic Anemia;UntreatedDrug: HerombopagInstitute of Hematology & Blood Diseases HospitalJiangsu Hengrui Pharmaceuticals Co.,LtdRecruiting18 YearsN/AAll54Phase 2China

63. Idiopathic thrombocytopenic purpura


Clinical trials : 391 Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT05685420
(ClinicalTrials.gov)
January 23, 20236/1/2023Extension Study of Herombopag for Pediatric Patients With Chronic Immune ThrombocytopeniaExtension Study of Herombopag in Children and Adolescents With Chronic Primary Immune ThrombocytopeniaImmune ThrombocytopeniaDrug: HerombopagJiangsu HengRui Medicine Co., Ltd.NULLNot yet recruiting6 Years17 YearsAll117Phase 3NULL